Placental growth factor at 24-28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia

This study aims to evaluate the safety of discontinuing aspirin treatment at 24-28 weeks in women at high risk after first-trimester combined screening for preeclampsia (PE) and normal placental growth factor (PlGF) levels at 24-28 weeks of gestation. This is a post hoc analysis of the StopPRE trial...

Full description

Bibliographic Details
Authors: Ricart, Marta|||0000-0003-0099-6525, Bonacina, Erika|||0000-0002-8042-8247, García Manau, Pablo|||0000-0002-2415-1626, López, Monica, Caamiña Álvarez, Sara|||0000-0001-9178-3132, Vives, Àngels|||0000-0001-9712-6379, Lopez-Quesada, Eva|||0000-0002-4477-3246, Maroto, Anna|||0000-0003-3225-9095, de Mingo, Laura, Pintado, Elena, Ferrer Costa, Roser|||0000-0002-8925-3172, Martin, Lourdes|||0000-0003-1781-5305, Rodriguez-Zurita, Alicia|||0000-0003-4177-4726, Garcia Cancela, Esperanza|||0000-0001-8924-9096, Pallarols Badia, Mar, Pratcorona Alicart, Laia|||0000-0002-3805-1589, Teixidor, Mireia|||0000-0001-8548-1648, Orizales Lago, Carmen María|||0000-0001-7184-2799, Ocaña, Vanesa|||0000-0003-2547-5646, del Barco, Ester|||0000-0002-1484-9027, Carreras Moratonas, Elena|||0000-0003-3471-7248, Suy, Anna|||0000-0003-2987-6105, Mendoza, Manel|||0000-0002-3030-3833
Format: article
Publication Date:2024
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:302986
Online Access:https://ddd.uab.cat/record/302986
https://dx.doi.org/urn:doi:10.1111/aogs.14955
Access Level:Open access
Keyword:Aspirin
PlGF
Preeclampsia
Salicylic acid
Screening preeclampsia
Description
Summary:This study aims to evaluate the safety of discontinuing aspirin treatment at 24-28 weeks in women at high risk after first-trimester combined screening for preeclampsia (PE) and normal placental growth factor (PlGF) levels at 24-28 weeks of gestation. This is a post hoc analysis of the StopPRE trial, conducted at nine Spanish maternity hospitals from September 2019 to September 2021. In the StopPRE trial, all high-risk single pregnancies identified during first-trimester screening for PE were treated with 150 mg of daily aspirin. Out of 1604 eligible women with a soluble fms-like tyrosine kinase-1 to PlGF ratio (sFlt-1/PlGF) ≤38 at 24-28 weeks, 968 were randomly assigned in a 1:1 ratio to either continue aspirin until 36 weeks (control group) or discontinue it (intervention group). In this secondary analysis, only women with PlGF ≥100 pg/mL at 24-28 weeks were included. As in the StopPRE trial, the non-inferiority margin was set at a 1.9% difference in preterm PE incidence between the groups. Among the 13 983 screened pregnant women, 1984 (14.2%) were deemed high-risk for preterm PE, of which 397 (20.0%) were ineligible, 636 declined participation, and 32 were excluded. Ultimately, 919 women with PlGF.

Similar Items